Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Africanews (styled as africanews) is a 24/7 pan-African multilingual news network located in Lyon, France previously headquartered in Pointe-Noire, Republic of the Congo. The news channel began broadcasting online, and via TV and satellite on 20 April 2016. [ 1 ]
Regeneron will also get a tax break on about $50 million of the renovation costs at the site, with exemptions of up to about $4.19 million in state and local sales taxes, according to IDA documents.
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.
Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's ...
Pan-African: Africanews, Africa 24, Presse Africaine, Africable (French), A24 news channel, Arise News, Africa Independent Television, TVC News (English). Portugal: RTP África is a pay television channel aimed at the Portuguese-speaking African countries, owned by the public broadcasting organisation of Portugal (RTP).
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo